Eli Lilly

News

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

AZ gets European approvals for Forxiga in chronic kidney dis...

AstraZeneca's Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with chronic kidney disease, extending its lead over rival drugs in the class.

News

Lilly has a bad hair day as Pfizer rival hits the mark in al...

Eli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer reported that its ritlecitinib improved scalp hair regrowth in a late-stage tria

News

Lilly sets out its stall on donanemab as filing approaches

The FDA's approval of Biogen's Aduhelm for Alzheimer's disease has emboldened Eli Lilly to move forward plans to file its own candidate donanemab later this year, although it acknowledges i

News

Lilly grabs glucose-sensing insulin tech, buying Protomer in...

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to b

News

Boehringer, Lilly hail Jardiance data in hard-to-treat heart...

Boehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance therapy in heart failure with preserved ejection fraction (HFpEF), a form of chr

News

AZ closes on Forxiga kidney disease label in EU after nod fr...

AstraZeneca's fast-growing SGLT2 inhibitor Forxiga could soon get a further boost from approval in the EU as a treatment for chronic kidney disease (CKD) in adults with and without type-2 d

AZ gets European approvals for Forxiga in chronic kidney dis...

Lilly has a bad hair day as Pfizer rival hits the mark in al...

Lilly sets out its stall on donanemab as filing approaches

Lilly grabs glucose-sensing insulin tech, buying Protomer in...

Boehringer, Lilly hail Jardiance data in hard-to-treat heart...

AZ closes on Forxiga kidney disease label in EU after nod fr...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Eli Lilly

Editor's Picks